和黄医药(00013.HK)12月于美国及新加坡展示治疗血小板减少症药物数据

阿斯达克财经
06 Nov 2024

和黄医药(00013.HK) 公布,旗下治疗成人原发免疫性血小板减少症药物“索乐匹尼布”的ESLIM-01 III期研究,以及其自主研发的化合物数项研究的最新及更新后的数据,将于今年12月7至10日在美国圣地亚哥召开的2024年美国血液学会年会,以及今年12月6至8日在新加坡召开的2024年欧洲肿瘤内科学会亚洲年会上公布。(js/w)

(港股报价延迟最少十五分钟。沽空资料截至 2024-11-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10